A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

被引：5
|
作者：
Vaishampayan, Ulka N.
Narayan, Vivek
Wise, David
Lang, Joshua Michael
Lowentritt, Benjamin H.
Mellado, Begona
Carles, Joan
Saez, M. Isabel
Abida, Wassim
Taplin, Mary-Ellen
Azad, Arun
Wang, Karrie
Barbash, Olena
Ferron-Brady, Geraldine
Fecteau, Doug
Khaled, Ahmed Hussein
Dhar, Arindam
De Bono, Johann S.
机构：
[1] Karmanos Canc Ctr, Detroit, MI USA
[2] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[3] New York Univ Med Ctr, New York, NY USA
[4] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA
[5] Chesapeake Urol Associates, Towson, MD USA
[6] Hosp Clin Barcelona, Barcelona, Spain
[7] Vall Hebron Univ Hosp Inst Oncol, Barcelona, Spain
[8] H Univ Virgen Victoria Reg Malaga, Inst Biomed Res Malaga CNIO IBIMA Genitourinary C, CRIS Canc Fdn Prostate Canc Res Grp, Malaga, Spain
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Dana Farber Canc Inst, Boston, MA USA
[11] Monash Univ, Clayton, Vic, Australia
[12] GlaxoSmithKline, Collegeville, PA USA
[13] Inst Canc Res & Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.TPS391
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS391
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies
    Borthakur, Gautam
    Dawson, Mark A.
    Stein, Eytan M.
    Karadimitris, Anastasios
    Huntly, Brian J. P.
    Dickinson, Michael J.
    Chaidos, Aristeidis
    Horner, Thierry
    Brennan, John
    Baron, January
    Kremer, Brandon E.
    Dhar, Arindam
    BLOOD, 2016, 128 (22)
  • [2] A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER plus breast cancer
    Sparano, Joseph A.
    Cescon, David W.
    Oliveira, Mafalda
    Stover, Daniel G.
    Tan-Chiu, Elizabeth
    Kremer, Brandon Edward
    Barbash, Olena
    Wu, Yuehui
    Mathew, Lijoy
    Cunningham, Elizabeth Ann
    Carpenter, Christopher L.
    Ballas, Marc S.
    Dhar, Arindam
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER plus breast cancer
    Pluard, Timothy
    Oh, Sun Young
    Oliveira, Mafalda
    Cescon, David
    Tan-Chiu, Elizabeth
    Wu, Yuehui
    Carpenter, Chris
    Cunningham, Elizabeth
    Ballas, Marc
    Dhar, Arindam
    Sparano, Joseph
    CANCER RESEARCH, 2018, 78 (04)
  • [4] A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.
    Patnaik, Akash
    Kung, Justin
    Loda, Massimo
    Taplin, Mary-Ellen
    Lis, Rosina
    Kantoff, Philip W.
    Balk, Steven P.
    Bubley, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [5] A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.
    Patnaik, Akash
    Loda, Massimo
    Kung, Justin
    Wu, Jim
    Taplin, Mary-Ellen
    Kantoff, Philip W.
    Cantley, Lewis
    Balk, Steven P.
    Bubley, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] A phase IB/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer.
    Del Priore, Giuseppe
    Hoffman, Steve
    Nixon, Daniel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
    Shore, Neal D.
    Efstathiou, Eleni
    Patel, Rupal
    Xu, Rongda
    Johnson, Ann
    Multani, Pratik S.
    Morris, Michael J.
    Abida, Wassim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
    Corman, J.
    Dawson, N.
    Hall, S.
    Nabhan, C.
    Ferrari, A.
    Armstrong, A. J.
    Murdock, M. I.
    Stewart, F.
    Sheikh, N.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2012, 23 : 311 - 311
  • [9] A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Small, Eric Jay
    Lance, Raymond
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Stubbs, Andrew
    McCoy, Candice
    DeVries, Todd
    Redfern, Charles H.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [10] A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer
    Wise, David R.
    Gardner, Olivia
    Gilbert, Houston N.
    Rieger, Aimee
    Paoloni, Melissa Constance
    Krishnan, Kartik
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345